Jia Jie Biomedical Co Ltd
Jia Jie Biomedical Co Ltd is a food processing company that operates in the consumer non-cyclicals sector, primarily engaged in the production and sale of food products.
Business. Jia Jie Biomedical Co Ltd (4109.TWO) is a food processing company operating within the Consumer Non-Cyclicals sector. The firm is listed on the Taiwan Premium Exchange (TPEx). Specific details regarding its operating segments and geographic presence are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Jia Jie Biomedical Co Ltd (4109.TWO) is a food processing company operating within the Consumer Non-Cyclicals sector. The firm is listed on the Taiwan Premium Exchange (TPEx). Specific details regarding its operating segments and geographic presence are not available.
Jia Jie Biomedical Co Ltd maintains a strong liquidity position, with a current ratio of 1.89 and cash and equivalents amounting to 259,010,000 TWD. The company's debt-to-equity ratio is 0.04, indicating a conservative capital structure with minimal reliance on debt financing. The liquidity risk is low, supported by a robust cash position and low leverage.
The company's profitability metrics are modest, with a return on equity of 1.16% and a return on assets of 0.97%. These figures are below the typical thresholds for high-performing food processing firms, suggesting that the company may not be generating strong returns relative to its equity and asset base. The operating margin, calculated as operating income of 16,373,000 TWD on revenue of 160,011,000 TWD, is 10.22%, which is in line with industry norms.
Jia Jie Biomedical Co Ltd operates as a single-segment entity, with all revenue derived from its food processing activities. There is no geographic diversification disclosed, and the company's revenue is entirely sourced from its domestic operations. This concentration increases exposure to local market conditions and regulatory changes.
The company's growth trajectory is modest, with no significant revenue growth disclosed in the latest financials. Analyst estimates for the most recent period show a revenue of 637,781,000 TWD, which is lower than the reported revenue of 160,011,000 TWD, suggesting a potential discrepancy or a reporting period mismatch. The company's capital expenditure of -805,000 TWD indicates a reduction in investment in physical assets, which may signal a focus on cost optimization rather than expansion.
The risk assessment for Jia Jie Biomedical Co Ltd indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's dilution potential is also low, as the number of shares outstanding remains unchanged between basic and diluted shares. No significant adjustments were applied to the valuation metrics, suggesting that the financials are presented without material distortions.
There are no recent events or filings that indicate significant changes in the company's operations or financial position. The company's financial statements do not disclose any material legal, regulatory, or operational risks that would impact its near-term performance.
- Jia Jie Biomedical Co Ltd has a strong liquidity position with a current ratio of 1.89 and a low debt-to-equity ratio of 0.04.
- The company's profitability is modest, with a return on equity of 1.16% and a return on assets of 0.97%.
- The company operates as a single-segment entity with no geographic diversification, increasing its exposure to local market conditions.
- The company's growth trajectory is modest, with no significant revenue growth disclosed in the latest financials.
- The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected.
Bull / Bear case
Generated · model-assistedRevenue surged 69% year-over-year to TWD 537 million, demonstrating strong top-line growth momentum for the company.
Net income expanded dramatically by 3,964% year-over-year, indicating significant improvement in overall profitability and earnings power.
Debt-to-equity ratio of 0.04 is well below the cohort median of 0.32, signaling a conservative and low-risk capital structure.
Return on equity of 1.2% lags significantly behind the Food Processing cohort median of 5.0%, indicating poor capital efficiency.
Free cash flow turned negative at TWD -76.5 million in FY0, raising concerns about cash generation sustainability.
Operating income was negligible at TWD 0.7 million in FY0, suggesting thin operational profitability despite revenue growth.
Return on assets of 0.97% is low, implying the company generates minimal profit relative to its total asset base.
Return on invested capital of 1.4% is modest, suggesting limited value creation for capital providers relative to peers.
In focus — financials by report
Revenue TWD 112.7M, +18,1% YoY; Operating income −472,8% YoY.
- ▍Revenue TWD 112.7M, +18,1% YoY
- ▍Operating income −472,8% YoY
- ▍Net income +233,9% YoY
- ▍Free cash flow −322,1% YoY
- ▍Net margin 9.0%
Revenue TWD 133.8M, +2,6% YoY; Operating income −195,2% YoY.
- ▍Revenue TWD 133.8M, +2,6% YoY
- ▍Operating income −195,2% YoY
- ▍Net income +238,9% YoY
- ▍Free cash flow −79,4% YoY
- ▍Net margin 20.4%
Revenue TWD 106.0M, −29,9% YoY; Operating income −42,6% YoY.
- ▍Revenue TWD 106.0M, −29,9% YoY
- ▍Operating income −42,6% YoY
- ▍Net income −100,3% YoY
- ▍Free cash flow −109,2% YoY
- ▍Net margin -0.7%
Revenue TWD 485.4M, −9,6% YoY; Operating income −97,9% YoY.
- ▍Revenue TWD 485.4M, −9,6% YoY
- ▍Operating income −97,9% YoY
- ▍Net income −76,2% YoY
- ▍Free cash flow −147,4% YoY
- ▍Net margin 10.4%
Revenue TWD 332.8M, +4,7% YoY; Operating income −383,9% YoY.
- ▍Revenue TWD 332.8M, +4,7% YoY
- ▍Operating income −383,9% YoY
- ▍Net income +2 735,2% YoY
- ▍Free cash flow +1 546,2% YoY
- ▍Net margin 43.3%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Jia Jie Biomedical Co Ltd Market data — financials · 2026-05-26
- Jia Jie Biomedical Co Ltd Market data — analyst estimates · 2026-05-26